Calgb (Alliance) 40603: Long-Term Outcomes (Ltos) After Neoadjuvant Chemotherapy (Nact) Plus /- Carboplatin (Cb) And Bevacizumab (Bev) In Triple-Negative Breast Cancer (Tnbc).William M. Sikov,Mei-Yin Polley,Erin Twohy,Charles M. Perou,Baljit Singh,Donald A. Berry,Sara M. Tolaney,George Somlo,Elisa R. Port,Cynthia X. Ma,Charles S. Kuzma,Eleftherios P. Mamounas,Mehra Golshan,Jennifer Ruth Bellon,Deborah E. Collyar,Olwen Mary Hahn,Clifford A. Hudis,Eric P. Winer,Ann H. Partridge,Lisa A. CareyJOURNAL OF CLINICAL ONCOLOGY（2019）引用 52|浏览79暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
